APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

English version České info

The rapid evolution of Human Immunodeficiency Virus (HIV-1) allows studies of ongoing host–pathogen interactions. One key selective host factor is APOBEC3G (hA3G) that can cause extensive and inactivating Guanosine-to-Adenosine (G-to-A) mutation on HIV plus-strand DNA (termed hypermutation). HIV can inhibit this innate anti-viral defense through binding of the viral protein Vif to hA3G, but binding efficiency varies and hypermutation frequencies fluctuate in patients. A pivotal question is whether hA3G-induced G-to-A mutation is always lethal to the virus or if it may occur at sub-lethal frequencies that could increase viral diversification. We show in vitro that limiting-levels of hA3G-activity (i.e. when only a single hA3G-unit is likely to act on HIV) produce hypermutation frequencies similar to those in patients and demonstrate in silico that potentially non-lethal G-to-A mutation rates are ∼10-fold lower than the lowest observed hypermutation levels in vitro and in vivo. Our results suggest that even a single incorporated hA3G-unit is likely to cause extensive and inactivating levels of HIV hypermutation and that hypermutation therefore is typically a discrete “all or nothing” phenomenon. Thus, therapeutic measures that inhibit the interaction between Vif and hA3G will likely not increase virus diversification but expand the fraction of hypermutated proviruses within the infected host.

Vyšlo v časopise: APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon. PLoS Genet 8(3): e32767. doi:10.1371/journal.pgen.1002550
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002550

Souhrn

Zdroje

1. RambautAPosadaDCrandallKAHolmesEC 2004 The causes and consequences of HIV evolution. Nat Rev Genet 5 52 61

2. HacheGManskyLMHarrisRS 2006 Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 8 148 57

3. MalimMH 2009 APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364 675 87

4. SimonVZennouVMurrayDHuangYHoDD 2005 Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1 e6 doi:10.1371/journal.ppat.0010006

5. ZhangHYangBPomerantzRJZhangCArunachalamSC 2003 The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 94 8

6. HarrisRS 2008 Enhancing immunity to HIV through APOBEC. Nat Biotechnol 26 1089 90

7. MalimMH 2006 Natural resistance to HIV infection: The Vif-APOBEC interaction. C R Biol 329 871 5

8. KyprJMrazekJ 1987 Unusual codon usage of HIV. Nature 327 6117 20

9. BerkhoutBvan HemertFJ 1994 The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res 22 1705 11

10. BerkhoutBde RondeA 2004 APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. Aids 18 1861 3

11. GaoFChenYLevyDNConwayJAKeplerTB 2004 Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J Virol 78 2426 33

12. KeeleBFGiorgiEESalazar-GonzalezJFDeckerJMPhamKT 2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105 7552 7

13. DeforcheKCamachoRLaethemKVShapiroBMoreauY 2007 Estimating the Relative Contribution of dNTP Pool Imbalance and APOBEC3G/3F Editing to HIV Evolution In Vivo. J Comput Biol 14 1105 14

14. SorosVBYonemotoWGreeneWC 2007 Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 3 e15 doi:10.1371/journal.ppat.0030015

15. MangeatBTurelliPCaronGFriedliMPerrinL 2003 Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 99 103

16. BishopKNVermaMKimEYWolinskySMMalimMH 2008 APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4 e1000231 doi:10.1371/journal.ppat.1000231

17. YuQKonigRPillaiSChilesKKearneyM 2004 Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11 435 42

18. SuspeneRSommerPHenryMFerrisSGuetardD 2004 APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32 2421 9

19. VartanianJPMeyerhansASalaMWain-HobsonS 1994 G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A 91 3092 6

20. ArmitageAEKatzourakisAde OliveiraTWelchJJBelshawR 2008 Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol 82 8743 61

21. SheehyAMGaddisNCMalimMH 2003 The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9 11 1404 7

22. GandhiSKSilicianoJDBaileyJRSilicianoRFBlanksonJN 2007 The role of APOBEC3G/F-mediated hypermutation in the control of HIV-1 in Elite Suppressors. J Virol 82 3125 30

23. KiefferTLKwonPNettlesREHanYRaySC 2005 G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79 1975 80

24. JaniniMRogersMBirxDRMcCutchanFE 2001 Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75 7973 86

25. NewmanENHolmesRKCraigHMKleinKCLingappaJR 2005 Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15 166 70

26. HolmesRKKoningFABishopKNMalimMH 2007 APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282 2587 95

27. HuthoffHAutoreFGallois-MontbrunSFraternaliFMalimMH 2009 RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5 e1000330 doi:10.1371/journal.ppat.1000330

28. XuHChertovaEChenJOttDERoserJD 2006 Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360 247 56

29. KaiserSMEmermanM 2006 Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80 875 82

30. MbisaJLBarrRThomasJAVandegraaffNDorweilerIJ 2007 Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81 7099 110

31. LangloisMANeubergerMS 2008 Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol 82 4660 4

32. WurtzerSGoubardAMammanoFSaragostiSLecossierD 2006 Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol 80 3679 83

33. SuspeneRRusniokCVartanianJPWain-HobsonS 2006 Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34 4677 84

34. JernPRussellRAPathakVKCoffinJM 2009 Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog e1000367 doi:10.1371/journal.ppat.1000367

35. FurukawaANagataTMatsugamiAHabuYSugiyamaR 2009 Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. Embo J 28 440 51

36. PybusOGRambautABelshawRFreckletonRPDrummondAJ 2007 Phylogenetic evidence for deleterious mutation load in RNA viruses and its contribution to viral evolution. Mol Biol Evol 24 845 52

37. SanjuanRMoyaAElenaSF 2004 The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101 8396 401

38. WangQBarrIGuoFLeeC 2008 Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene. Rna 14 2478 88

39. HarrisRSBishopKNSheehyAMCraigHMPetersen-MahrtSK 2003 DNA deamination mediates innate immunity to retroviral infection. Cell 113 803 9

40. HarrisRSSheehyAMCraigHMMalimMHNeubergerMS 2003 DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4 641 3

41. YangBChenKZhangCHuangSZhangH 2007 Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem 282 11667 75

42. SadlerHAStengleinMDHarrisRSManskyLM 2010 APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84 7396 404

43. KimEYBhattacharyaTKunstmanKSwantekPKoningFA 2010 Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 84 10402 5

44. KapoorAJonesMShaferRWRheeSYKazanjianP 2004 Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol 78 7112 23

45. HauserAMugenyiKKabasinguziRKuechererCHarmsG 2011 Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS ONE 6 e20357 doi:10.1371/journal.pone.0020357

46. SvarovskaiaESMoserMJBaeASPrudentJRMillerMD 2006 MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol 44 4237 41

47. D'AquilaRTGerettiAMHortonJHRouseEKheshtiA 2011 Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Res Hum Retroviruses 27 201 9

48. HazenRLanierER 2003 Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 32 255 8

49. TurrizianiOSchuetzJDFocherFScagnolariCSampathJ 2002 Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368 325 32

50. SchuetzJDConnellyMCSunDPaibirSGFlynnPM 1999 MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5 1048 51

51. WijnholdsJMolCAvan DeemterLde HaasMSchefferGL 2000 Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97 7476 81

52. BantiaSAnanthSLParkerCDHornLLUpshawR 2003 Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor–BCX-1777. Int Immunopharmacol 3 879 87

53. EbrahimiDAnwarFDavenportMP 2011 APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. J Virol 85 9139 46

54. WoodNBhattacharyaTKeeleBFGiorgiELiuM 2009 HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5 e1000414 doi:10.1371/journal.ppat.1000414

55. FouratiSMaletIBinkaMBoukobzaSWirdenM 2010 Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids 24 2313 21

56. MulderLCOomsMMajdakSSmedresmanJLinscheidC 2010 Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84 9613 7

57. BouraraKLieglerTJGrantRM 2007 Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog 3 e153 doi:10.1371/journal.ppat.0030153

58. MulderLCHarariASimonV 2008 Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 105 5501 6

59. RousseauCMDanielsMGCarlsonJMKadieCCrawfordH 2008 HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 82 6434 46

60. ChenJHongKJiaMLiuHZhangY 2007 Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC). Retrovirology 4 62

61. YuXGLichterfeldMAddoMMAltfeldM 2005 Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? Curr Med Chem 12 6 741 7

62. AddoMMYuXGRosenbergESWalkerBDAltfeldM 2002 Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 21 671 8

63. NovitskyVCaoHRybakNGilbertPMcLaneMF 2002 Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76 10155 68

64. AltfeldMAddoMMEldridgeRLYuXGThomasS 2001 Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 167 2743 52

65. KiepielaPNgumbelaKThobakgaleCRamduthDHoneyborneI 2007 CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13 46 53

66. PaceCKellerJNolanDJamesIGaudieriS 2006 Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80 9259 69

67. LandAMBallTBLuoMPilonRSandstromP 2008 Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82 8172 82

68. Vazquez-PerezJAOrmsbyCEHernandez-JuanRTorresKJReyes-TeranG 2009 APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6 23

69. UlengaNKSarrADHamelDSankaleJLMboupS 2008 The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24 1285 90

70. PiantadosiAHumesDChohanBMcClellandRSOverbaughJ 2009 Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 83 7805 14

71. SimonJHSoutherlingTEPetersonJCMeyerBEMalimMH 1995 Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 69 4166 72

72. BishopKNHolmesRKSheehyAMDavidsonNOChoSJ 2004 Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004. 14 1392 6

73. BishopKNHolmesRKSheehyAMMalimMH 2004 APOBEC-mediated editing of viral RNA. 305 645

74. ReedSEStaleyEMMayginnesJPPintelDJTullisGE 2006 Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods 138 85 98

75. TsengWCHaseltonFRGiorgioTD 1997 Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression. J Biol Chem 272 25641 7

76. StadenRBealKFBonfieldJK 2000 The Staden package Methods Mol Biol 132 115 30

77. RosePPKorberBT 2000 Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 16 400 1

78. KijakGHJaniniLMTovanabutraSSanders-BuellEArroyoMA 2008 Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376 101 11